REG - Novacyt S.A. - Acquisition update

Novacyt SAAnnouncement

17/08/2023 17:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230817:nRSQ6954Ja&default-theme=true

RNS Number : 6954J  Novacyt S.A.  17 August 2023

 

Novacyt S.A.

("Novacyt", the "Company" or the "Group")

 

Acquisition update

 

Paris, France and Eastleigh, UK - 17 August 2023 - Novacyt (EURONEXT GROWTH:
ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, notes
today's announcement by Yourgene Health plc ("Yourgene"), in relation to the
recommended cash offer made by Novacyt UK Holdings Limited ("Novacyt UK"), a
wholly-owned subsidiary of Novacyt, for the entire issued and to be issued
share capital of Yourgene announced on 3 July 2023 (the "Acquisition"), which
is to be effected by means of a Court-sanctioned scheme of arrangement under
Part 26 of the Companies Act 2006 (the "Scheme"). A circular in relation to
the Scheme was published by Yourgene on 27 July 2023 (the "Scheme Document").

 

Capitalised terms used in this announcement shall, unless otherwise defined,
have the same meaning as set out in the Scheme Document.

 

At the Court Meeting and the General Meeting held earlier today, convened in
accordance with an order of the Court dated 26 July 2023, all resolutions to
approve and implement the Scheme were passed by the requisite majorities of
Yourgene's shareholders.

 

Yourgene's full announcement can be found here:
polaris.brighterir.com/public/yourgenehealth/news/rns/story/
(https://polaris.brighterir.com/public/yourgenehealth/news/rns/story/xp39emw)

xp39emw
(https://polaris.brighterir.com/public/yourgenehealth/news/rns/story/xp39emw)
 

 

The Acquisition remains subject to the satisfaction or (where applicable)
waiver of the remaining Conditions and to the further terms set out in Part
III of the Scheme Document, including the Court sanctioning the Scheme at the
Court Sanction Hearing and the delivery of a copy of the Court Order to the
Registrar of Companies. The expected timetable of principal events for the
implementation of the Scheme remains as set out in the Scheme Document. The
dates are indicative only and are subject to change. The dates will depend,
among other things, on the date upon which: (i) the Conditions are satisfied
or (if capable of waiver) waived; (ii) the Court sanctions the Scheme; and
(iii) a copy of the Court Order is delivered to the Registrar of Companies.

 

Contacts

 

 Novacyt SA                                                +44 (0)23 8074 8830
 James Wakefield, Non-Executive Chairman

 James McCarthy, Acting Chief Executive Officer

 Numis (Financial Adviser and Joint Broker to Novacyt and Financial Adviser to           +44 (0)20 7260 1000
 Novacyt UK)
 Freddie Barnfield / Stuart Ord / Duncan Monteith / Jack McLaren

 SP Angel Corporate Finance LLP (Nominated Adviser and Joint Broker to Novacyt)          +44 (0)20 3470 0470

 Matthew Johnson / Charlie Bouverat (Corporate Finance)

 Vadim Alexandre / Rob Rees (Corporate Broking)

 Allegra Finance (French Listing Sponsor)                                                 +33 (1) 42 22 10 10

                                                                                       r.durgetto@allegrafinance.com (mailto:r.durgetto@allegrafinance.com) /
 Rémi Durgetto / Yannick Petit                                                           y.petit@allegrafinance.com (mailto:y.petit@allegrafinance.com)

 Walbrook PR (Financial PR & IR)                           +44 (0)20 7933 8780

 Stephanie Cuthbert / Anna Dunphy / Phillip Marriage       novacyt@walbrookpr.com (mailto:novacyt@walbrookpr.com)

 

About Novacyt Group

Novacyt is an international diagnostics business delivering a broad portfolio
of in vitro and molecular diagnostic tests for a wide range of infectious
diseases, enabling faster, more accurate, accessible testing to improve
healthcare outcomes. The Company provides customers with a seamless
sample-to-result workflow using its integrated and scalable
instrumentation/solutions. The Company specialises in the design, manufacture,
and supply of real-time PCR kits, reagents and a full range of laboratory and
qPCR instrumentation for molecular biology research and clinical use. Novacyt
offers one of the world's most varied and comprehensive range of qPCR assays,
covering human, veterinary, biodefence, environmental, agriculture and food
testing.

 

Novacyt is headquartered in Vélizy in France with offices in Stokesley and
Eastleigh, UK, and is listed on the London Stock Exchange's AIM market
("NCYT") and on the Paris Stock Exchange Euronext Growth ("ALNOV").

 

For more information, please refer to the website: www.novacyt.com
(http://www.novacyt.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ACQPRMFTMTBBBAJ